Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSCs in Moderate/Severe Rheumatoid Arthritis
NCT03798028Unknown
- Sponsor
- Xijing Hospital
- Start
- Dec 2017
- Primary completion
- Dec 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Randomised, double-blind trial of human umbilical cord mesenchymal stem cells in rheumatoid arthritis (RA) (2 arms), sponsored by Xijing Hospital. Primary endpoints: Improvement rate of blood routine hemoglobin (HGB) compared to baseline at 24 weeks and Improvement rate of forced vital capacity (FVC) and/or carbon monoxide diffusing capacity (DLCO) compared to baseline at 24 weeks. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03798028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03798028.